NCT03580382 · Interventional trial
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
Overall registry status Terminated
Phase 1 · Phase 2
Conditions Melanoma
Delaware Valley sites
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory